Recent Updates
Recently added Catalysts
PRCT Positive Sentiment Score: 75/100

PROCEPT BioRobotics to Present at Upcoming 2024 Wells Fargo Healthcare Conference on September 4, 2024

Key Takeaway: PROCEPT BioRobotics, a surgical robotics company, will present at the 2024 Wells Fargo Healthcare Conference on September 4, 2024. The presentation will highlight their innovative solutions in urology, particularly their AI-Powered HydroSTM Robotic System designed for effective Aquablation therapy. This therapy is aimed at treating lower urinary tract symptoms associated with BPH, which affects about 40 million men in the U.S. An archived webcast of the presentation will be available on the company's website after the event.

Market Sentiment Analysis

POSITIVE FACTORS

  • PROCEPT BioRobotics is showcasing its advancements in surgical robotics at a major healthcare conference.
  • The company has a unique AI-Powered robotic technology for Aquablation therapy.
  • Aquablation therapy addresses a significant market, helping millions suffering from lower urinary tract symptoms.

Full Press Release Details

SAN JOSE, Calif., Aug. 28, 2024 (GLOBE NEWSWIRE) -- PROCEPT BioRobotics® (Nasdaq: PRCT) (the “Company”), a surgical robotics company focused on advancing patient care by developing transformative solutions in urology, today announced that members of management will present at the upcoming 2024 Wells Fargo Healthcare Conference in Boston, Massachusetts. Management is scheduled to present on Wednesday, September 4 at 1:30 p.m. Eastern Time.
A live webcast of each event, as well as an archived recording, will be available on the “Investors” section of the company’s website at: https://ir.procept-biorobotics.com. The webcasts will be archived and available for replay for at least 90 days after the event.
About PROCEPT BioRobotics Corporation
PROCEPT BioRobotics is a surgical robotics company focused on advancing patient care by developing transformative solutions in urology. The HYDROSTM Robotic System is the only AI-Powered, robotic technology that delivers Aquablation therapy. PROCEPT BioRobotics designed Aquablation therapy to deliver effective, safe, and durable outcomes for males suffering from lower urinary tract symptoms or LUTS, due to BPH that are independent of prostate size and shape or surgeon experience. BPH is the most common prostate disease and impacts approximately 40 million men in the United States. The Company has developed a significant and growing body of clinical evidence with over 150 peer-reviewed publications, supporting the benefits and clinical advantages of Aquablation therapy.
VP, Investor Relations and Business Operations

Frequently Asked Questions

When will PROCEPT BioRobotics present at the conference?

PROCEPT BioRobotics will present on September 4, 2024, at 1:30 p.m. ET.

Where can I watch the presentation live?

The live presentation can be viewed on the company's 'Investors' webpage.

What is the HYDROSTM Robot System?

The HYDROSTM Robot System is an AI-powered technology for Aquablation therapy.

What condition does Aquablation therapy treat?

Aquablation therapy addresses lower urinary tract symptoms due to BPH.

How many peer-reviewed publications support Aquablation?

There are over 150 peer-reviewed publications backing Aquablation therapy.

Last updated: Aug 28, 2024